No connection

Search Results

CCEL vs TELA

CCEL
Cryo-Cell International, Inc.
BEARISH
Price
$3.67
Market Cap
$29.6M
Sector
Healthcare
AI Confidence
95%
TELA
TELA Bio, Inc.
BEARISH
Price
$0.63
Market Cap
$28.2M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
CCEL
--
TELA
--
Forward P/E
CCEL
183.5
TELA
-1.12
P/B Ratio
CCEL
-1.61
TELA
4.44
P/S Ratio
CCEL
0.95
TELA
0.35
EV/EBITDA
CCEL
31.86
TELA
-1.07

Profitability

Gross Margin
CCEL
63.53%
TELA
68.17%
Operating Margin
CCEL
9.96%
TELA
-31.86%
Profit Margin
CCEL
-8.52%
TELA
-48.37%
ROE
CCEL
--
TELA
-223.35%
ROA
CCEL
0.19%
TELA
-25.12%

Growth

Revenue Growth
CCEL
-3.6%
TELA
18.2%
Earnings Growth
CCEL
-80.5%
TELA
--

Financial Health

Debt/Equity
CCEL
--
TELA
9.13
Current Ratio
CCEL
0.62
TELA
4.21
Quick Ratio
CCEL
0.55
TELA
3.4

Dividends

Dividend Yield
CCEL
16.35%
TELA
--
Payout Ratio
CCEL
3962.91%
TELA
0.0%

AI Verdict

CCEL BEARISH

CCEL exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a negative Price/Book ratio of -1.61, suggesting negative shareholder equity. The company's dividend is fundamentally unsustainable with a payout ratio of 3962.91%, indicating that dividends are being paid out of capital or debt rather than earnings. While gross margins remain strong, the combination of declining YoY revenue (-3.60%) and crashing earnings growth (-80.50%) creates a precarious outlook. Liquidity is a critical concern with a current ratio of 0.62, placing the firm at significant short-term financial risk.

Strengths
Strong gross margins at 63.53%
Positive operating margin of 9.96%
Low Price/Sales ratio of 0.95
Risks
Negative equity as indicated by Price/Book ratio of -1.61
Severe liquidity risk with a current ratio of 0.62 and quick ratio of 0.55
Unsustainable dividend payout ratio (3962.91%)
TELA BEARISH

TELA exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9 and a catastrophic ROE of -223.35%. While the company maintains a strong gross margin (68.17%) and modest revenue growth (18.2%), these are completely offset by extreme leverage (Debt/Equity of 9.13) and a consistent 25-quarter history of negative earnings. The stock's 5-year price collapse of 95.4% reflects a fundamental loss of investor confidence that is not countered by any meaningful insider buying or operational profitability.

Strengths
Strong Gross Margin of 68.17% indicating product value
Positive YoY Revenue Growth of 18.20%
High Current Ratio (4.21) providing short-term liquidity
Risks
Extreme financial leverage with a Debt/Equity ratio of 9.13
Severe lack of profitability with an ROE of -223.35%
Critical financial health as indicated by a Piotroski F-Score of 1/9

Compare Another Pair

CCEL vs TELA: Head-to-Head Comparison

This page compares Cryo-Cell International, Inc. (CCEL) and TELA Bio, Inc. (TELA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile